RA Pharmaceuticals initiated with a Buy at Stifel. Stifel analyst Stephen Willey started RA Pharmaceuticals with a Buy rating and $55 price target. The positive Phase 2 proof-of-concept zilucoplan data generated in generalized myasthenia gravis and paroxysmal nocturnal hemoglobinuria “cement the validity of the zilucoplan value proposition and significantly de-risk” future Phase 3 development plans, Willey tells investors in a research note. He believes RA shares at current levels remain “significantly underappreciated by investors.”
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.